Anavex Life Sciences Corporation News - AVXL

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Anavex...

Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:...

Form 8-K - Current report

Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference

ANAVEX®2-73 corrects directly to humans’ translatable EEG biomarkers in a model of Fragile X Syndrome (FXS...

Form S-3 - Registration statement under Securities Act of 1933

Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference

Oral, once daily blarcamesine significantly slowed clinical decline for early Alzheimer's disease patients with...

Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact...

kund 18 minutes ago

He is still looking for those signals, so NEVER...no urgency in the land of TGD.

👺 1 ❌️ 1

nidan7500 22 minutes ago

georgejji, SHORT SQUEEZE for AVXL coming soon!!!

OK, what will trigger that ? TIA.

👍️ 1

Hoskuld 31 minutes ago

When do you think we get OLE data release?

👍️ 1

Jonjones325 1 hour ago

Maybe we can get our FOMO run when our MAA is accepted. We never got ours and my mom says it's not fair!

👍️ 2

georgejjl 1 hour ago

SHORT SQUEEZE for AVXL coming soon!!!

Good luck and GOD bless

👍️0

kevindenver 1 hour ago

Nice, you may have nailed the recent low!

I'm long Jan $5 Calls for a wee bit of leverage.

👍️ 1

kevindenver 2 hours ago

At the individual stock level I feel $6 is an important level that can be met with the broader market alone, but I think $AVXL needs a news event for any decent substantial holdable upside move, and that could come in the form of news from a PR and provide the volume needed for a positive technical move.

On the broader front, the 1/2 point USA FED cut should keep the money flowing and buoy jobs. Jobs = money moving = good economy = good equity markets at ALL market caps and dividends.

I'm watching $RUT, $XBI, $IBB, and $IBBQ for signs I'm right or wrong. But damn!!! These indexes are at or near triple and quadruple tops!?! Definitely keeping it interesting.

👍️ 1

georgejjl 2 hours ago

Expect nearly 8 million shares or more of AVXL stock to be bought this week and at a high for the week!!!

Good luck and GOD bless,

👍️0

LakeshoreLeo1953 2 hours ago

Just curious Steady....
No Options in my Roth.
Do you use in-the-money short term
Or pay the time premium on longer term trades?

👍️0

Steady_T 2 hours ago

Closed out my Friday $5 options by exercise.

👍️ 2

georgejjl 2 hours ago

Expect AVXL to close at or near the high of the day, today!!!

Good luck and GOD bless,

👍️0

LakeshoreLeo1953 4 hours ago

a reason to move much higher (hopefully above the down slant hitting around $6.20 to $6.25 appx.

I would say that 15% is much more realistic than "LIFTOFF" proponents.
Only issue is would a move to that level be 25% from near term opportunity?

👍️0

Hoskuld 5 hours ago

He does have significant input, as do other members of the team. That is what I already wrote.

👍️ 1

bb8675309 5 hours ago

Neurodegenerative Disease-Focused Anavex Life Sciences' Alzheimer's Candidate Slows Disease Progression By Almost 39%

blarcamesine (ANAVEX2-73), once daily orally, significantly slowed clinical decline in people with early Alzheimer’s disease (AD).

https://finance.yahoo.com/news/neurodegenerative-disease-focused-anavex-life-123916806.html

👍️ 4

powerwalker 5 hours ago

Kudos, george, as your prediction on interest rates are surely propelling stocks forward ... for today, at least.

👍️ 2

mike_dotcom 5 hours ago

No news this week. Didn't George promise?

👺 1 ❌️ 1

sab63090 8 hours ago

What a potential "set up" for an advance!
The reaction to the rate cut with the very light decline provided the bulls a great reason to surprise the market today if the futures are accurate. The $IBB and $XBI look right for a big push up which might just give $AVXL a reason to move much higher (hopefully above the down slant hitting around $6.20 to $6.25 appx.

Yes, Investor where in the heck is the TLR? why is this being held up? results?

👍️ 1

Investor2014 11 hours ago

Just always remember one can only trust small trial results from Anavex and never from any other biotech - WGT!

PS! this includes of course drip fed post hoc updates often over more than a year since failed TLR.

👍️ 1 👺 1 ❌️ 1

kund 13 hours ago

Dr Missling exhibits quite a deal of confidence He's an expert at kicking the can down the road and telling lies. He closes his eyes because he doesn’t want to see people's faces when he lies. Guy is clown, he has been repeating same tape for last 3year and still not able to file EMA.

👍️ 1 👺 1 ❌️ 1

georgejjl 14 hours ago

As can be seen when viewing the following video, Dr Missling exhibits quite a deal of confidence in using blarcamesine and a treatment for Alzheimer's

https://journey.ct.events/view/b72fd686-0547-49f0-ab66-b1e4959753a1

Thank you Pasakorius on stocktwits for the link.

Good luck and GOD bless,

👍️ 1

catdaddy 17 hours ago

And you are kidding yourself if you think he doesn’t have significant input!

👍️ 3

Hoskuld 17 hours ago

You are kidding yourself if you think Dr. Jin is in charge of trial design. That is not in his job title or list of responsibilities. He contributes as a member of the team, no doubt, but he is not in charge. It is clear that you have never worked in biopharm and that is OK - but your musings are not accurate.

👍️ 2 👺 3 ❌️ 3

sab63090 18 hours ago

Ken:
We recently learned that my wife who never has had ANY medical problems has just been prescribed some drops which I have to put in every day for her since they see glaucoma developing and is scheduled to see our ophthalmologist on 9/24...she was referred to someone who handles both glaucoma and cataract surgery....I had both eyes done last year for cataracts and don't require glasses for distance, just reading....give me advice if you have something I should consider.....no macular degeneration nor a vitreous hemorrhage was mentioned, this is her 3rd doctor in the office, mine said she needed to see someone else, then the new doctor referred her to this one (all in the same practice)....best, Steve

👍️0

sab63090 18 hours ago

Tom:
Maybe it holds, so let's see how the next 2 days help to establish a potential inflections level! I'm just standing pat for now.

Steve

👍️0

Kentucky123 19 hours ago

I have glaucoma, macular degeneration and a vitreous hemorrhage currently so may not be seeing clearly.

👍️ 1

123tom 20 hours ago

Maybe your moving avg. support line has a chance to hold now? We'll see soon enough. Price movements are not staying tight in technical trading. It's more volatile with larger moves. Up 50cents, down 50 cents.... but the whole playing field is 1 dollar (5 to 6) small, small steps, but the price is climbing and tumbling 2 and 3 steps at a time. In this range.

👍️ 2

LakeshoreLeo1953 20 hours ago

Anyone who didn’t doesn’t deserve an opinion.
As with my original .72 entry.
Never existed as NASDAQ listing.
Therefore.....1:4

👺 1 ❌️ 1

sab63090 20 hours ago

Both the $IBB and $XBI both look better to me! ha ha.....so let's expect $AVXL to catch up....😃

👍️0

Hosai 20 hours ago

Actually just realized they did a phase 2a too, though also fairly small with 48 patients.

👍️0

Kentucky123 20 hours ago

XBI is at resistance as well. 103 has been tested several times and is a real barrier. The most advertised rate cut in history has not as yet been the catalyst so many expected. Momentum is waning in the sector but volume is not lacking.
AVXL would be considered a special situation if peer review or EMA submission were to occur. Absent any news this should go the way of XBI.

👍️ 1

mike_dotcom 21 hours ago

"This is a news driven stock" True - it goes down on ANY news.

👺 1 🤩 1 ❌️ 1

Steady_T 21 hours ago

That is always the question, how do macro economics affect the micro economics.
AVXL exists in a bubble right now.

The SP is controlled by the big players.

This is a news driven stock, till that changes, the players control.

👍️ 1

Hosai 21 hours ago

Also on a practical level can't see the EMA loving the storage/transport and infusion aspect of the Longeveron drug:

"Cell-based therapies like Lomecel-B, which use live mesenchymal stem cells (MSCs), are generally sensitive to temperature fluctuations. To maintain cell viability, they often need to be stored and transported at ultra-low temperatures, typically in the range of -80°C to -196°C (cryopreservation in liquid nitrogen).

Maintaining these low temperatures is crucial because exposure to non-ideal conditions can reduce the cells' viability and therapeutic efficacy. Special cryogenic transport systems would likely be used for this purpose, similar to what is done with other cellular therapies like CAR-T cell treatments.

Hospitals and infusion centers administering Lomecel-B would need proper storage facilities, such as cryogenic freezers, and trained staff for handling and thawing cells before administration."

👍️ 5

mike_dotcom 21 hours ago

I see we were up 20 cents at one point - that's the AUTOMATIC SELL signal. It NEVER fails. The stock remains a total POS.

👺 1 ❌️ 1

Talon38 21 hours ago

Lacey, Falconer, Nidan, its positive that this cite allows us to share medical and curbside knowledge that sometimes comes from little trial "n". Meanwhile millions suffer and die while formal drug development follows the slow gathering of statistics and presentation before world agencies! We understand the need for safety and efficacy, but those with approval authority are by in large state salaried bureaucrats who are not prone to "reach for the stars". I fully appreciate operating within safe guidelines being an Air Force Flight Safety Officer for many years, but I also knew that lives depended on rapid mission accomplishment in "life or death" contingencies. So what I am leading to is, with millions ww facing disease degradation and death, the medical establishment and drug approval authorities need to go to war with the enemy and not rely on job safety and commercial politics. We as a country lose more of our children, parents and grandparent each year than in all the military conflicts on the horizon. If we forced all of our defense industry in time of conflict to operate at peacetime development speed, we would not be a free nation today. The medical drug industry is at war every day and countless are falling each day ........sound the bugle!!

👍️ 5 💥 1

sab63090 21 hours ago

Gundlach Interview on CNBC: this is one very smart person and I think he's correct...looking at Commodity Prices kind of points to a weaker economy....look at Energy Prices with Crude Prices hanging near their lows! Refreshing to hear his points.

👍️0

Hosai 22 hours ago

Yes but based on a phase 1 study with 33 patients.
It was for 26 weeks and the Hippocampal finding was with completed (n) of 7 placebo, 9 low dose and 8 high dose. Obv also was exploratory endpoint, high dose spikes at 13 weeks but is falling back closer to placebo at 26 weeks.
Also in terms of the ADAS COG they didn't find stat significance which slightly goes against what he was saying but maybe that's why he seemed to be arguaing ADAS COG wasn't the best measure at one point.
https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.12651

👍️ 2

sab63090 22 hours ago

3 Days dancing around the 200 day sma and the price level seems ok to me, so I'll probably get hit on "Terrible Thursday"....I kind of like where the price is albeit without conviction with price and volume!

Not far away from breaking the down slant line @ around $6.20 to $6.25 so I should expect an effort by the mm's (and their buddies, the hedge fund guys) to put a big effort to stop the push up from happening, if not we might just surprise.

👍️ 1

sab63090 22 hours ago

that makes sense, boi568

👍️0

sab63090 22 hours ago

I sense that the people who are borrowing money, I.e. using their credit cards to pay ongoing bills will have a big effect eventually with minimum payments so the banks will be reducing access and the borrowers will be overwhelmed and will stop "buying things"....not sure when but I think it will stop the consumer from spending.

👍️ 2

tredenwater2 22 hours ago

Very nice link, ty. Dr. Missling did very well amongst his peers.

👍️ 5

frrol 22 hours ago

Interesting to note: at minute 46 the Longeveron rep says his company did just that in their small POC trial: they detected and publicly showed a potential correlation of brain (hippocampal) volume improvement of their drug to cognitive benefit (MOCA and MMSE).

👍️0

georgejjl 23 hours ago

Fed cuts interest rates by a half-point

https://www.washingtonpost.com/business/2024/09/18/fed-meeting-interest-rate-cut-decision-live-fomc/

That is GREAT NEWS for the US and world economies and GREAT NEWS for AVXL stock.

Good luck and GOD bless,

😡 1 🤢 1

IhidfromtheX 23 hours ago

Multiply that .17 x 4!

👍️0

IhidfromtheX 23 hours ago

When you're five months into a year to live, one will gamble on what one is learning is real and works. Lots of crap papers out there...

👍️ 1

LakeshoreLeo1953 23 hours ago

I “put it in” to hopefully afvantange the yin/yang of the absolutists.

.17 2013
and
5.30 2024

Is the oft cited clairvoyance.
IF you accept that…does it fit YOUR results?

👺 1 ❌️ 1

boi568 23 hours ago

He will probably PR the filing upon the EMA accepting it.

👍️ 2

Hosai 23 hours ago

Yes I thought in general he spoke quite well even though obv nothing new revealed.
Annovis' plan seems overly optimistic but if FDA were receptive it would be a good sign in how flexible they were becoming.
I believe Annovis are planning to do an 18 month phase 3 trial but after 6 months plan to apply to FDA with an NDA based on the 6 months for symtopmatic treament and then will expand it to disease modifying after 18 months data. I don't see how they unblind the 6 months data to make this application without interfering with the 18 month trial however.

👍️ 3

Jonjones325 24 hours ago

I wonder if Missling will PR the MAA filing or just the acceptance of it.

I’m hoping he does both of course.

👍️ 4

frrol 24 hours ago

Thanks for posting. 9 minutes in, Missling points out that correlation of AB reduction to cognition response has not yet been "described" (studied and disclosed), saying that it may be because there is none.

We too, however, have not provided cognition correlations for our brain volume,mAB ratio, etc biomarker results (this will cause whining from who don't read). This is one of several things the paper needs to "describe", along with S1 status correlation. Missling is implying saying here that they will be for our trial, and reviewed in future scientific talks. Let's see, looking forward to them.

👍️ 1 👺 1 ❌️ 1

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Anavex Life Sciences Corporation (AVXL)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

AVXL News

Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update

Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024

Form 8-K - Current report

Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference

Form S-3 - Registration statement under Securities Act of 1933

Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference

Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Form 4 - Statement of changes in beneficial ownership of securities

Anavex Life Sciences Announces Expansion of Leadership Team

Form 4 - Statement of changes in beneficial ownership of securities

Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ

Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

AVXL Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Anavex Life Sciences Corporation (AVXL) News

Anavex Life Sciences Corporation (AVXL)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

AVXL News

Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update

Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024

Form 8-K - Current report

Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference

Form S-3 - Registration statement under Securities Act of 1933

Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference

Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Form 4 - Statement of changes in beneficial ownership of securities

Anavex Life Sciences Announces Expansion of Leadership Team

Form 4 - Statement of changes in beneficial ownership of securities

Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ

Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

AVXL Discussion

Your Recent History

Company

Business

Popular

Get The App